7 results
To select targeted treatment based on ex vivo kinase activity inhibition profiles to targeted agents of tumor tissue from patients with advanced cancer for whom no standard treatment is available.
The aim of this study is to evaluate the effect of a single oral dose of TW001 on oxidative stress and pharmacokinetics with and without food. Dosing with an oral solution is considered to have major advantages over iv dosing in a chronic condition…
Primary objectives Phase I: To determine the recommended phase 2 dose (RP2D) of the lapatinib-trametinib combination in patients with KRASm NSCLC Phase II: To determine the progression free survival of the lapatinib-trametinib combination compared…
To evaluate the long-term safety of FAB122 in patients with ALS.
To assess the effect of treatment with 100 mg of FAB122 (edaravone) on disease progression in patients with ALS.
The objective of this study is the determination of the diagnostic quality (sensitivity, specificity, positive predictive value, negative predictive value) for the detection of malignant or pre-malignant tumor with the DELSENI in comparison with…
Primary: The co-primary objectives of this study are* to compare independently adjudicated progression-free survival (PFS) following treatment with neratinib pluscapecitabine versus lapatinib plus capecitabine in patients with HER2-positive (HER2+)…